[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-001", "question": "A 45-year-old with severe ARDS on VV-ECMO develops suspected heparin-induced thrombocytopenia (4T score 6). Heparin is discontinued and argatroban initiated. The patient has significant hemolysis (plasma free hemoglobin 800 mg/dL). Which monitoring assay is most reliable for titrating argatroban in this setting?", "options": ["Activated partial thromboplastin time (aPTT)", "Anti-Xa chromogenic assay", "Anti-IIa (thrombin) chromogenic assay", "Activated clotting time (ACT)", "Dilute Russell viper venom time (dRVVT)"], "answer": "C", "answer_index": 2, "explanation": "Anti-IIa chromogenic assay directly measures thrombin inhibition by argatroban and is least affected by hemolysis, platelet count, or factor consumption seen in ECMO. aPTT is unreliable due to factor deficiency and hemolysis. Anti-Xa assays measure anti-Xa activity, not direct thrombin inhibitors. ACT is affected by platelets and fibrinogen. dRVVT is used for lupus anticoagulant detection.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me work through this problem systematically.\n\nThe patient has:\n1. Severe ARDS on VV-ECMO\n2. Suspected HIT (4T score 6 = intermediate-high probability)\n3. Argatroban initiated (direct thrombin inhibitor)\n4. Significant hemolysis (plasma free hemoglobin 800 mg/dL)\n\nThe question asks about the most reliable monitoring assay for argatroban in the setting of significant hemolysis.\n\nLet me consider each option:\n\nA. aPTT - This is the standard monitoring test for argatroban. However, aPTT can be affected by hemolysis because free hemoglobin interferes with optical detection methods used in many coagulators.\n\nB. Anti-Xa chromogenic assay - This measures anti-Xa activity, which is not the mechanism of argatroban (a direct thrombin/factor IIa inhibitor). This would not be appropriate for monitoring argatroban.\n\nC. Anti-IIa (thrombin) chromogenic assay - Argatroban is a direct thrombin (factor IIa) inhibitor. Chromogenic assays are less affected by hemolysis compared to clot-based assays because they measure color change from substrate cleavage rather than clot formation. This would directly measure argatroban's effect on thrombin.\n\nD. ACT - Activated clotting time is commonly used during ECMO but is affected by many variables including hemolysis, hemodilution, and platelet count. It's less specific and can be unreliable in hemolysis.\n\nE. dRVVT - This is primarily used for lupus anticoagulant testing, not for monitoring direct thrombin inhibitors.\n\nThe key issue here is hemolysis. Clot-based assays (aPTT, ACT, dRVVT) can be significantly affected by hemolysis because:\n- Free hemoglobin interferes with optical detection\n- Hemolysis releases phospholipids and other factors\n\nChromogenic assays are more resistant to interference from hemolysis because they measure enzymatic activity through color change rather than clot formation.\n\nSince argatroban is a direct thrombin inhibitor, the anti-IIa chromogenic assay would be the most reliable and specific test in this setting with significant hemolysis.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-002", "question": "A 62-year-old with metastatic pancreatic adenocarcinoma on gemcitabine presents with acute kidney injury (creatinine 3.2 mg/dL), platelet count 45,000/µL, schistocytes, LDH 2200 IU/L, and haptoglobin <10 mg/dL. ADAMTS13 activity is 35%. What is the most appropriate initial management?", "options": ["Urgent plasma exchange", "Eculizumab therapy", "Discontinue gemcitabine and provide supportive care", "Rituximab 375 mg/m² weekly", "Caplacizumab 10 mg daily"], "answer": "C", "answer_index": 2, "explanation": "Gemcitabine-induced thrombotic microangiopathy is a drug-mediated toxicity, not complement-mediated or immune-mediated. ADAMTS13 is not severely deficient (<10%), excluding TTP. Plasma exchange is ineffective. Eculizumab and caplacizumab are reserved for complement-mediated aHUS. Rituximab is for TTP. The cornerstone of management is immediate discontinuation of gemcitabine.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nThe patient presents with:\n- Metastatic pancreatic adenocarcinoma on gemcitabine\n- Acute kidney injury (creatinine 3.2 mg/dL)\n- Thrombocytopenia (platelets 45,000/µL)\n- Schistocytes (microangiopathic hemolytic anemia)\n- Elevated LDH (2200 IU/L)\n- Low haptoglobin (<10 mg/dL)\n- ADAMTS13 activity 35%\n\nThis is a thrombotic microangiopathy (TMA) picture with MAHA + thrombocytopenia + organ damage.\n\nKey diagnostic consideration: The ADAMTS13 activity of 35% is important. In TTP (thrombotic thrombocytopenic purpura), ADAMTS13 activity is typically <10% (severely deficient). An ADAMTS13 level of 35% essentially rules out TTP.\n\nThis presentation is most consistent with drug-induced TMA from gemcitabine. Gemcitabine is a well-known cause of drug-induced TMA, which typically presents with:\n- Renal failure (prominent feature)\n- MAHA\n- Thrombocytopenia\n- ADAMTS13 activity is NOT severely reduced (usually >10-20%)\n\nManagement considerations:\n- Option A (Plasma exchange): This is first-line for TTP, but ADAMTS13 >10% makes TTP unlikely. Plasma exchange is not effective for drug-induced TMA.\n- Option B (Eculizumab): Used for atypical HUS (complement-mediated TMA), not typically first-line for drug-induced TMA.\n- Option C (Discontinue gemcitabine and supportive care): This is the appropriate management for drug-induced TMA. Removing the offending agent is crucial.\n- Option D (Rituximab): Used for immune-mediated TTP with ADAMTS13 antibodies, not applicable here.\n- Option E (Caplacizumab): Anti-vWF agent used in TTP, not indicated when ADAMTS13 is 35%.\n\nFor gemcitabine-induced TMA, the primary treatment is discontinuation of the drug and supportive care. Some cases may benefit from eculizumab if refractory, but the initial step is always stopping the causative agent.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-003", "question": "A 28-year-old presents 2 hours after ingesting barium carbonate with profuse vomiting, diarrhea, and profound muscle weakness. Serum potassium is 2.1 mEq/L with ST-segment depression on ECG. What is the primary mechanism of hypokalemia and most effective elimination strategy?", "options": ["GI losses; emergent hemodialysis", "Intracellular shift via K+ channel blockade; oral sodium sulfate", "Renal tubular wasting; potassium-sparing diuretics", "Beta-agonist effect; beta-blockade therapy", "Insulin-mediated shift; IV insulin with glucose"], "answer": "B", "answer_index": 1, "explanation": "Barium blocks voltage-gated potassium channels (Kv), preventing cellular efflux and causing intracellular K+ sequestration. Hemodialysis is ineffective due to barium's large volume of distribution (1.5 L/kg). Oral sodium sulfate precipitates residual Ba2+ as insoluble BaSO4 in the GI tract if administered within 24 hours, preventing further absorption. Massive IV potassium replacement is necessary but does not address elimination.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case of barium carbonate poisoning.\n\nClinical Presentation:\n- Profuse vomiting and diarrhea\n- Profound muscle weakness\n- Severe hypokalemia (K+ 2.1 mEq/L)\n- ECG changes (ST-segment depression)\n\nMechanism of Barium Toxicity:\nBarium is a potassium channel blocker. It blocks the rectifying potassium channels (Kir channels) in cell membranes, which prevents potassium from leaving cells. This causes:\n1. Intracellular shift of potassium (not primarily GI losses)\n2. Hypokalemia\n3. Muscle weakness/paralysis\n4. Cardiac arrhythmias\n\nTreatment Strategy:\nThe key treatment for barium poisoning involves:\n1. Sodium sulfate or magnesium sulfate - This precipitates barium as insoluble barium sulfate in the GI tract, preventing further absorption\n2. Aggressive potassium replacement\n3. Supportive care\n\nHemodialysis can remove barium but is not the primary elimination strategy - the most effective approach is to prevent absorption by forming insoluble barium sulfate in the gut.\n\nAnalyzing the options:\n- A: GI losses is not the primary mechanism (it's intracellular shift); hemodialysis is not the most effective strategy\n- B: Correctly identifies K+ channel blockade causing intracellular shift; oral sodium sulfate is the most effective elimination strategy (precipitates barium in GI tract)\n- C: Renal tubular wasting is not the mechanism\n- D: Not a beta-agonist effect\n- E: Not insulin-mediated\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-004", "question": "A 3-month-old infant presents with intractable seizures, hypotonia, and developmental regression. Brain MRI shows bilateral globus pallidus hyperintensity. Plasma creatine level is low. Which test provides the most specific diagnosis for guanidinoacetate methyltransferase (GAMT) deficiency?", "options": ["Plasma guanidinoacetate measurement", "Urine creatine:creatinine ratio", "Cerebrospinal fluid guanidinoacetate level", "GAMT gene sequencing", "Brain magnetic resonance spectroscopy"], "answer": "C", "answer_index": 2, "explanation": "CSF guanidinoacetate is the most sensitive and specific biomarker for GAMT deficiency due to accumulation behind the blood-brain barrier. Plasma GAA can be normal in mild cases. Urine ratio is supportive but nonspecific. GAMT sequencing may miss deep intronic variants or large deletions. MRS shows absent creatine peak but does not identify the specific enzyme defect.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me work through this question about GAMT deficiency diagnosis.\n\nGAMT (guanidinoacetate methyltransferase) deficiency is one of the creatine deficiency syndromes. In this condition:\n- GAMT converts guanidinoacetate (GAA) to creatine\n- When GAMT is deficient, GAA accumulates and creatine is low\n\nThe clinical presentation described (intractable seizures, hypotonia, developmental regression, bilateral globus pallidus hyperintensity on MRI, low plasma creatine) is consistent with GAMT deficiency.\n\nLet me evaluate each option:\n\nA. Plasma guanidinoacetate measurement - In GAMT deficiency, GAA is markedly elevated because it cannot be converted to creatine. This is the key biochemical marker that distinguishes GAMT deficiency from other creatine deficiency syndromes (like AGAT deficiency where GAA is low, or creatine transporter deficiency where GAA is normal).\n\nB. Urine creatine:creatinine ratio - This is elevated in creatine transporter deficiency but not specific for GAMT deficiency.\n\nC. CSF guanidinoacetate level - While GAA would be elevated in CSF in GAMT deficiency, plasma measurement is more accessible and equally diagnostic.\n\nD. GAMT gene sequencing - This provides definitive genetic confirmation but is typically done after biochemical testing suggests the diagnosis.\n\nE. Brain MRS - Shows decreased creatine peak, which indicates creatine deficiency but doesn't distinguish between the different types of creatine deficiency syndromes.\n\nThe question asks for the \"most specific diagnosis\" for GAMT deficiency. While gene sequencing (D) would be definitive, the plasma guanidinoacetate measurement (A) is the most specific biochemical test that distinguishes GAMT deficiency from other creatine deficiency syndromes. Elevated GAA with low creatine is pathognomonic for GAMT deficiency.\n\nIn clinical practice, elevated plasma GAA is the specific diagnostic marker for GAMT deficiency, making it the best initial specific test.\n\nThe answer is (A)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-005", "question": "A 58-year-old develops progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, and gait ataxia over 18 months. CSF shows mild lymphocytic pleocytosis. Which antibody and pathological finding are most characteristic?", "options": ["Anti-Hu; neuronal nuclear inclusions", "Anti-NMDA receptor; perivascular lymphocytic cuffing", "Anti-IgLON5; tau deposition in brainstem and hypothalamus", "Anti-LGI1; faciobrachial dystonic seizures", "Anti-GAD65; cerebellar Purkinje cell loss"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease presents with sleep dysfunction (non-REM parasomnia, obstructive apnea) and bulbar symptoms, distinct from other autoimmune encephalitides. Unlike typical antibody-mediated diseases, it is characterized by tauopathy (4R-tau deposition) in the brainstem and hypothalamus on autopsy, correlating with poor response to immunotherapy. Anti-Hu is associated with small cell lung cancer and sensory neuropathy. Anti-LGI1 presents with faciobrachial dystonic seizures and hyponatremia.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nThe patient presents with:\n- Progressive non-REM parasomnia\n- Obstructive sleep apnea\n- Bulbar dysfunction\n- Gait ataxia\n- 18-month progression\n- CSF showing mild lymphocytic pleocytosis\n\nThis constellation of symptoms - particularly the combination of sleep disorders (non-REM parasomnia, sleep apnea), bulbar dysfunction, and gait ataxia - is highly characteristic of anti-IgLON5 disease.\n\nAnti-IgLON5 disease is a unique condition that bridges autoimmune and neurodegenerative disorders. Key features include:\n- Sleep disorders (non-REM and REM parasomnias, obstructive sleep apnea, stridor)\n- Bulbar symptoms (dysphagia, dysarthria, stridor)\n- Gait instability/ataxia\n- Movement disorders\n- Cognitive decline\n\nThe pathological hallmark of anti-IgLON5 disease is tau deposition (a tauopathy) predominantly affecting the brainstem tegmentum and hypothalamus, which explains the sleep and bulbar manifestations.\n\nLet me rule out other options:\n- A. Anti-Hu: Associated with sensory neuronopathy, encephalomyelitis, but not this specific sleep disorder pattern\n- B. Anti-NMDA receptor: Typically presents with psychiatric symptoms, seizures, movement disorders, autonomic instability in younger patients\n- D. Anti-LGI1: Characterized by faciobrachial dystonic seizures and limbic encephalitis, not this sleep pattern\n- E. Anti-GAD65: Associated with stiff person syndrome, cerebellar ataxia, but not this specific sleep disorder constellation\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-006", "question": "During VV-ECMO for severe ARDS, the circuit suddenly shows extensive air with the patient becoming pulseless. What is the immediate management step?", "options": ["Place patient in left lateral decubitus and Trendelenburg position while continuing pump", "Clamp venous line, stop pump, aspirate from arterial port", "Increase ECMO flow to 6 L/min to clear air emboli", "Administer 100% oxygen and initiate CPR", "Convert circuit to VA-ECMO configuration"], "answer": "B", "answer_index": 1, "explanation": "In VV-ECMO, air embolism is venous. The immediate action is to stop the pump to halt further embolization, clamp the venous line to prevent additional air entry, and aspirate air from the arterial (outflow) line port. Durant's position is ineffective for venous emboli. Increasing pump flow worsens embolization. CPR is secondary to circuit management. Configuration change does not address the acute air emergency.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me work through this emergency scenario systematically.\n\nThe situation: VV-ECMO patient with sudden extensive air in the circuit and the patient is now pulseless.\n\nKey considerations:\n- Air embolism during ECMO is a life-threatening emergency\n- In VV-ECMO, air would be returned to the venous system and could pass through the lungs or through a PFO to the arterial circulation\n- The patient is pulseless, indicating cardiac arrest\n\nLet me evaluate each option:\n\nA. Left lateral decubitus and Trendelenburg position while continuing pump\n- This position helps trap air in the right ventricle apex, preventing it from entering the pulmonary circulation\n- However, continuing the pump would continue to push air into the patient - this is dangerous\n\nB. Clamp venous line, stop pump, aspirate from arterial port\n- This stops further air entry into the patient\n- Allows removal of air from the circuit\n- This is the standard approach for air in ECMO circuit\n\nC. Increase ECMO flow to 6 L/min to clear air emboli\n- This would push MORE air into the patient - absolutely contraindicated\n\nD. Administer 100% oxygen and initiate CPR\n- While the patient is pulseless and needs resuscitation, this doesn't address the source of the problem (ongoing air embolism)\n- CPR alone won't help if air continues to be pumped\n\nE. Convert circuit to VA-ECMO configuration\n- This is not an immediate step and would take time\n- Doesn't address the immediate air embolism crisis\n\nThe immediate priority is to STOP the source of air embolism. The standard protocol for air in ECMO circuit is to:\n1. Stop the pump immediately\n2. Clamp the lines to prevent air from reaching the patient\n3. Aspirate air from the circuit\n\nOption B addresses the immediate need to stop air from entering the patient and remove it from the circuit.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-007", "question": "A 22-year-old with relapsed ALL receives axicabtagene ciloleucel. On day 12, he develops status epilepticus and CT shows cerebral edema, unresponsive to methylprednisolone 1 g/day for 3 days. What is the most appropriate next therapy for steroid-refractory ICANS?", "options": ["Increase methylprednisolone to 2 g/day", "Anakinra 100 mg intravenously", "Tocilizumab 8 mg/kg intravenously", "Cyclophosphamide 500 mg/m²", "Therapeutic plasma exchange"], "answer": "B", "answer_index": 1, "explanation": "Anakinra, an IL-1 receptor antagonist, is the preferred therapy for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). Tocilizumab targets IL-6 and is effective for cytokine release syndrome but has limited efficacy for ICANS. Escalating steroids beyond 1 g/day provides minimal additional benefit. Cyclophosphamide is not used for ICANS. Plasma exchange would eliminate the therapeutic CAR-T cells.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case of steroid-refractory ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) following CAR-T cell therapy.\n\nThe patient has:\n- Relapsed ALL treated with axicabtagene ciloleucel (CAR-T therapy)\n- Day 12 post-infusion with status epilepticus and cerebral edema\n- Failed high-dose methylprednisolone (1 g/day × 3 days)\n\nThis represents severe, steroid-refractory ICANS (Grade 4 given status epilepticus and cerebral edema).\n\nLet me evaluate the options:\n\nA. Increase methylprednisolone to 2 g/day - The patient has already failed 3 days of high-dose steroids. Simply increasing the dose is unlikely to be effective and delays other interventions.\n\nB. Anakinra 100 mg IV - Anakinra is an IL-1 receptor antagonist that crosses the blood-brain barrier. It has emerged as a treatment option for steroid-refractory ICANS, as IL-1 signaling plays a role in neuroinflammation. Current guidelines support anakinra for steroid-refractory ICANS.\n\nC. Tocilizumab 8 mg/kg IV - While tocilizumab (IL-6 receptor antagonist) is first-line for CRS, it does NOT cross the blood-brain barrier effectively and is generally NOT recommended for ICANS. It may even theoretically worsen ICANS by increasing CNS IL-6 levels.\n\nD. Cyclophosphamide 500 mg/m² - This would eliminate the CAR-T cells but is not a standard approach for ICANS management and would compromise the therapeutic effect.\n\nE. Therapeutic plasma exchange - This has been used in refractory cases but is not the standard next step after steroid failure.\n\nFor steroid-refractory ICANS, current consensus guidelines recommend anakinra as it can penetrate the CNS and target the IL-1 pathway involved in neuroinflammation.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-008", "question": "A 35-year-old presents with refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g of sustained-release verapamil. High-dose insulin euglycemic therapy (HIET) is initiated. What is the optimal insulin dosing and monitoring frequency?", "options": ["0.5-1 unit/kg/hr; check glucose every 2 hours", "1-10 units/kg/hr; check glucose every hour", "0.1-0.5 units/kg/hr; check potassium every 4 hours", "5-20 units/kg/hr; check lactate every 2 hours", "2-5 units/kg/hr; check pH every 4 hours"], "answer": "B", "answer_index": 1, "explanation": "HIET for severe calcium channel blocker overdose requires supraphysiologic insulin doses of 1-10 units/kg/hr to overcome insulin resistance and maximize myocardial glucose uptake. Blood glucose must be monitored hourly to maintain euglycemia (150-200 mg/dL) with concurrent dextrose infusion. Lower doses are ineffective. Doses exceeding 10 units/kg/hr are not standard practice. Potassium and pH are monitored but glucose is the critical parameter.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "I need to recall the optimal dosing for High-dose Insulin Euglycemic Therapy (HIET) in calcium channel blocker toxicity.\n\nHIET is a key treatment for severe calcium channel blocker overdose causing cardiogenic shock. Let me consider the correct parameters:\n\nInsulin Dosing in HIET:\n- Standard HIET protocol typically involves:\n  - Bolus: 1 unit/kg IV\n  - Infusion: Starting at 1 unit/kg/hr, can be titrated up\n  - In severe/refractory cases, doses up to 10 units/kg/hr have been used\n  - The typical range cited is 1-10 units/kg/hr\n\nMonitoring:\n- Glucose must be monitored frequently (every 30-60 minutes initially, then hourly)\n- Potassium should also be monitored but glucose is the primary concern\n- Dextrose infusion is typically required to maintain euglycemia\n\nLet me evaluate the options:\n\nA. 0.5-1 unit/kg/hr; glucose every 2 hours - Dose is on the lower end, monitoring too infrequent\n\nB. 1-10 units/kg/hr; glucose every hour - This matches the standard HIET protocol for CCB toxicity\n\nC. 0.1-0.5 units/kg/hr; potassium every 4 hours - Dose too low for HIET, wrong monitoring focus\n\nD. 5-20 units/kg/hr; lactate every 2 hours - Doses higher than typically recommended, wrong monitoring parameter\n\nE. 2-5 units/kg/hr; pH every 4 hours - Dose range is reasonable but monitoring pH is not the primary concern\n\nThe correct answer should reflect:\n- Insulin dosing of 1-10 units/kg/hr (starting at 1, titrating up as needed)\n- Glucose monitoring every hour (or more frequently initially)\n\nOption B matches the established HIET protocol for calcium channel blocker toxicity.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-009", "question": "A 6-month-old male infant presents with severe eczema, petechiae, recurrent otitis media, and platelet count of 30,000/µL with small platelet volume. What is the most sensitive diagnostic test for Wiskott-Aldrich syndrome?", "options": ["WASP gene sequencing", "Platelet-associated antibody testing", "Lymphocyte subset enumeration", "WASP protein expression by flow cytometry", "Serum IgE and IgA levels"], "answer": "D", "answer_index": 3, "explanation": "Flow cytometry for WASP protein expression in lymphocytes is more sensitive than standard gene sequencing, which may miss large deletions, splice site mutations, or deep intronic variants. Absent or reduced WASP protein expression confirms the diagnosis. Platelet antibodies are negative. Lymphocyte subsets are variable. IgE is elevated and IgA is low but these are nonspecific.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Let me analyze this case of a 6-month-old male with the classic triad of Wiskott-Aldrich syndrome (WAS):\n- Severe eczema\n- Thrombocytopenia with small platelets (microthrombocytopenia)\n- Recurrent infections (otitis media)\n\nNow let me evaluate each diagnostic option:\n\nA. WASP gene sequencing - This is the gold standard for definitive diagnosis and can detect mutations in the WAS gene. It's highly specific and can identify the exact mutation, but it takes longer and may miss some mutations in regulatory regions.\n\nB. Platelet-associated antibody testing - This would be used for immune thrombocytopenia (ITP), not WAS. Not appropriate here.\n\nC. Lymphocyte subset enumeration - While patients with WAS may have lymphocyte abnormalities, this is not specific or sensitive for WAS diagnosis.\n\nD. WASP protein expression by flow cytometry - This test directly measures the WASP protein in lymphocytes/monocytes. It's rapid, relatively inexpensive, and highly sensitive. Absent or reduced WASP protein expression is diagnostic. This test can quickly identify patients with WAS and is often used as the initial screening test.\n\nE. Serum IgE and IgA levels - While WAS patients often have elevated IgE and IgA with low IgM, these findings are not specific to WAS.\n\nBetween options A and D:\n- Flow cytometry for WASP protein expression is considered the most sensitive initial diagnostic test because it directly detects the absence or reduction of the protein product. It's faster and can detect cases even when the specific mutation might be missed by sequencing.\n- Gene sequencing is the definitive/confirmatory test but may miss some mutations and takes longer.\n\nFor sensitivity as a screening/diagnostic test, WASP protein expression by flow cytometry is considered the most sensitive approach for initial diagnosis.\n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-010", "question": "A 28-year-old develops progressive myoclonus epilepsy, cerebellar ataxia, and visual loss over 3 years. EEG shows generalized spike-wave discharges. Which test is most specific for diagnosing Kufs disease (adult neuronal ceroid lipofuscinosis)?", "options": ["Epilepsy gene panel (SCN1A, GABRG2)", "Brain biopsy with periodic acid-Schiff staining", "Skin biopsy with electron microscopy", "CSF 14-3-3 protein immunoassay", "Serum anti-GAD65 antibody titer"], "answer": "C", "answer_index": 2, "explanation": "Electron microscopy of skin biopsy showing fingerprint profiles or granular osmiophilic deposits is the most specific diagnostic test for neuronal ceroid lipofuscinosis. Genetic testing (CLN6, CLN8, CTSF) is confirmatory but may be negative in variant forms. Brain biopsy is invasive and unnecessary. CSF 14-3-3 protein is elevated in Creutzfeldt-Jakob disease. Anti-GAD65 antibodies are associated with autoimmune epilepsy, not NCL.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nThe patient presents with:\n- Progressive myoclonus epilepsy\n- Cerebellar ataxia\n- Visual loss\n- Over 3 years duration\n- Age 28 years\n- EEG showing generalized spike-wave discharges\n\nThis clinical picture is classic for Kufs disease (adult neuronal ceroid lipofuscinosis/NCL).\n\nLet me evaluate each option:\n\nA. Epilepsy gene panel (SCN1A, GABRG2) - These genes are associated with genetic epilepsies like Dravet syndrome, not NCL. NCL involves different genes (CLN genes).\n\nB. Brain biopsy with periodic acid-Schiff staining - While brain biopsy could show storage material, it's invasive and PAS staining is not the most specific method for NCL.\n\nC. Skin biopsy with electron microscopy - This is the key diagnostic test for Kufs disease. NCL is characterized by accumulation of autofluorescent lipopigments (ceroid-lipofuscin) in lysosomes. Electron microscopy of skin (or other tissues) reveals characteristic ultrastructural inclusions - fingerprint profiles, curvilinear bodies, or granular osmiophilic deposits (GRODs). Skin biopsy is less invasive than brain biopsy and highly specific when these characteristic inclusions are identified.\n\nD. CSF 14-3-3 protein immunoassay - This is used for Creutzfeldt-Jakob disease (CJD), which has a much more rapid progression and different clinical features.\n\nE. Serum anti-GAD65 antibody titer - This is for autoimmune conditions like stiff-person syndrome or autoimmune epilepsy, not for storage diseases.\n\nFor Kufs disease specifically, skin biopsy with electron microscopy showing characteristic ultrastructural inclusions (fingerprint profiles, curvilinear bodies, or GRODs) is the most specific diagnostic test. While genetic testing for CLN genes is now also available, among the options given, electron microscopy of skin biopsy is the most specific test listed.\n\nThe answer is (C)"}]